NIS to Examine Disease Activity in SLE Patients Treated With Subcutaneous Anifrolumab in Routine Care

Recruiting now

Conditions studied: Lupus Erythematosus, Systemic

In brief

VIOLET is a prospective, single-arm, multi-centre, non-interventional study (NIS) evaluating real-world clinical and patient-reported outcome (PRO) data in adult patients who are initiated on subcutaneous anifrolumab treatment of systemic lupus erythematosus (SLE) in line with the applicable european summary of product characteristics (SmPC) and neither having used anifrolumab subcutaneous (SC) or intravenous (IV) before.

Key facts

Study ID

NCT07424261

Run by

AstraZeneca

People needed

125

Starts

2026-03-19

Expected to finish

2029-08-31

Last updated by the study team

2026-06-24

Who can join

Age: 18 and older, up to 130. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age ≥18 years at the time of signing the informed consent
• Diagnosis of SLE
• Prescription of anifrolumab SC in line with the european summary of product characteristics (SmPC)
• Prescription of anifrolumab SC was decided prior to and independently of the study
• Signed and dated written informed consent prior to enrolment into the study
• Willing and able to participate in all study evaluations and procedures

You may not qualify if…

• Prior exposure to anifrolumab
• Treatment with concurrent biologics
• Current or planned participation in a clinical study that does not constitute routine care
• Currently experiencing a severe or rapidly progressive Class III or IV glomerulonephritis requiring induction therapy (mycophenolate mofetil [MMF]/cyclophosphamide + high dose steroids), isolated Class V lupus nephritis (in absence of other SLE manifestations, i.e. skin/joint involvement), or active severe or unstable neuropsychiatric lupus
• Conditions (acute or chronic) or events at the time of signing the informed consent that would limit the patient's ability to complete questionnaires or participate in this study over the period of 24 months according to the treating physician (e.g., clinically significant cognitive impairment or dementia, unstable severe psychiatric illness, uncontrolled alcohol or substance use disorder that interferes with adherence to care or other circumstances that preclude completing PROs or attending routine visits)
• Pregnancy or breast feeding at study enrolment

Where it is running

• Research Site — Altenburg, Germany (enrolling)
• Research Site — Bad Bramstedt, Germany (enrolling)
• Research Site — Berlin, Germany (enrolling)
• Research Site — Chemnitz, Germany (enrolling)
• Research Site — Erlangen, Germany (enrolling)
• Research Site — Heidelberg, Germany (enrolling)
• Research Site — Herne, Germany (enrolling)
• Research Site — Kassel, Germany (enrolling)
• Research Site — Leipzig, Germany (enrolling)
• Research Site — Meerbusch-Lank, Germany (enrolling)
• Research Site — München, Germany (enrolling)
• Research Site — Planegg, Germany (enrolling)
• Research Site — Schwerin, Germany (enrolling)
• Research Site — Trier, Germany (enrolling)
• Research Site — Wetzlar, Germany (enrolling)
• Research Site — Wuppertal, Germany (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.